Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Compass Therapeutics (CMPX) Enterprise Value (2022 - 2026)

Compass Therapeutics' Enterprise Value history spans 5 years, with the latest figure at -$194.7 million for Q1 2026.

  • On a quarterly basis, Enterprise Value fell 71.98% to -$194.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$194.7 million, a 71.98% decrease, with the full-year FY2025 number at -$209.5 million, down 64.56% from a year prior.
  • Enterprise Value hit -$194.7 million in Q1 2026 for Compass Therapeutics, up from -$209.5 million in the prior quarter.
  • Over the last five years, Enterprise Value for CMPX hit a ceiling of -$101.5 million in Q2 2025 and a floor of -$219.9 million in Q3 2025.
  • Historically, Enterprise Value has averaged -$160.9 million across 5 years, with a median of -$166.2 million in 2023.
  • The widest YoY moves for Enterprise Value: up 35.7% in 2025, down 86.34% in 2025.
  • Tracing CMPX's Enterprise Value over 5 years: stood at -$186.6 million in 2022, then grew by 18.28% to -$152.5 million in 2023, then increased by 16.51% to -$127.3 million in 2024, then tumbled by 64.56% to -$209.5 million in 2025, then grew by 7.06% to -$194.7 million in 2026.
  • Business Quant data shows Enterprise Value for CMPX at -$194.7 million in Q1 2026, -$209.5 million in Q4 2025, and -$219.9 million in Q3 2025.